scholarly journals Leukemoid Reaction as a “Tumor Marker” in Breast Cancer

2012 ◽  
Vol 03 (05) ◽  
pp. 271-273 ◽  
Author(s):  
Chien-Hua Lin ◽  
Jyh-Cherng Yu ◽  
Jing-Jim Ou ◽  
Yueh-Tsung Lee ◽  
Hurng-Sheng Wu
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Leukemoid Reaction

Tumor marker levels elevate false-positively in postsurgical Breast Cancer patients with high sgpt levels or with receiving oral 5-FU or its derivatives

Breast Cancer ◽  
1999 ◽  
Vol 6 (3) ◽  
pp. 181-186
Author(s):  
Kazuhiko Asanuma ◽  
Yoshihisa Hama ◽  
Shinya Kobayashi ◽  
Kiyoshi Shingu ◽  
Shiro Yokoyama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Breast Cancer Patients

Association between molecular subtype of local advanced breast cancer with Ca 15-3 level

2021 ◽  
pp. 1-4
Author(s):  
Dony Ruswendro ◽  
Salman Ardi Syamsu ◽  
Rudy Thabry ◽  
Arifin Seweng ◽  
Andi Nilawati Usman
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Marker ◽  
Molecular Subtypes ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Tissue Growth ◽  
Advanced Breast ◽  
Luminal A ◽  
Luminal B

BACKGROUND: Neoplasm is an abnormal mass of tissue that grows excessively and not coordinated with normal tissue growth and continues to do so even though the stimulation that triggered the change has stopped. Breast cancer can be known by using tumor marker, which has been used is mucin-like glycoprotein Carcinoma Antigen (CA 15-3) which is a tumor marker that is specific to breast cancer. METHOD: This study is a cross-sectional study to determine the association between molecular subtypes of locally advanced breast cancer with CA 15-3 level at Abdul Wahab Sjahranie Samarinda Hospital. The population in this study were all breast cancer patients that were confirmed by histopathological examination. RESULTS: A total of 75 patients were included for this study, 29 patients (38.7%) known as Overexpression HER2, 18 patients (24.0%) were Luminal B with HER2 (+), 11 patients (14.7%) were Luminal B with HER2 (−), 11 patients (14.7%) were Basal-like/TNBC, and 6 patients (8,0%) were Luminal A. From the ANOVA test, the value of p = 0.045 (p < 0.05) means there was an association between Ca 15-3 level and molecular subtypes in patients with locally advanced breast cancer at the Abdul Wahab Sjahranie Hospital in Samarinda 2017. In this study Ca 15-3 levels were obtained on average for Luminal A 16.98 U/mL, Luminal B with HER2 (−) 42.41 U/mL, Luminal B with HER2 (+) 73.75 U/mL, Overexpression HER2 47.73 U/mL, and Basal Like /TNBC 63.50 U/mL. CONCLUSION: Statistically, it was found that there was an association between Ca 15-3 levels and molecular subtypes in patients with locally advanced breast cancer at the Abdul Wahab Sjahranie Hospital in Samarinda 2017.

TPA and CA 15.3 Measurements for Breast Cancer Monitoring in a Routine Setting

1999 ◽  
Vol 14 (1) ◽  
pp. 40-44 ◽  
Author(s):  
J. M.G. Bonfrer ◽  
C. M. Korse
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Roc Curves ◽  
Tumor Burden ◽  
Cell Turnover ◽  
Ca 15.3

TPA and CA 15.3 concentrations were routinely determined in serum of patients treated for breast cancer during a 15-month period. ROC curves did not show differences in the ability to differentiate between NED and PD on the basis of matching tumor marker values. During monitoring of patients with NED, TPA levels showed fluctuations of more than 25% that were not disease related. We concluded that CA 15.3 is a more slowly reacting marker of tumor burden than TPA, which is an immediate indicator of cell turnover.

scholarly journals Serum tumor marker levels at the development of intracranial metastasis in patients with lung or breast cancer

2019 ◽  
Vol 11 (5) ◽  
pp. 1765-1771 ◽  
Author(s):  
Naoya Ishibashi ◽  
Toshiya Maebayashi ◽  
Takuya Aizawa ◽  
Masakuni Sakaguchi ◽  
Masahiro Okada
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Serum Tumor Marker ◽  
Intracranial Metastasis

Mucin-Like Carcinoma-Associated Antigen (MCA) in Tissue and Serum of Patients with Breast Cancer: Clinical Applications in Prognosis and Disease Monitoring

1993 ◽  
Vol 8 (2) ◽  
pp. 113-123 ◽  
Author(s):  
R. Molina ◽  
J. Jo ◽  
X. Filella ◽  
G. Zanon ◽  
J.J. Grau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Tumor Size ◽  
Primary Breast Cancer ◽  
Statistical Significance ◽  
Metastatic Breast ◽  
Response To Treatment ◽  
Disease Monitoring ◽  
Nodal Involvement ◽  
Benign Diseases

Mucin-like Carcinoma-associated Antigen (MCA) has been associated with many breast cancers. The aim of this study was to evaluate MCA in tumor tissue and serum as a potential tumor marker for prognosis and disease monitoring. MCA levels were determined in the tissue of 196 patients with primary breast cancer, 25 with metastatic disease and 25 patients with benign diseases, in pellet and/or cytosol. MCA levels were also determined in the serum of 50 patients with benign diseases, 148 with primary breast cancer (Mo), 150 with metastatic breast cancer (MT), and 200 with no clinical evidence of disease (NED). MCA tissue concentrations in pellet and cytosol were similar: 66.7 + 251 U/mg and 41.1 + 53 U/mg, respectively. No relationship between MCA levels and tumor size or nodal involvement was found. Higher MCA levels were observed in patients with ER + or PgR + tumors than in those with ER- or PgR- tumors (p < 0.01). Patients with MCA pellet concentrations lower than 10 U/mg of protein had shorter disease - free intervals (DFI) than those with higher values (p < 0.05). Abnormally high serum levels of MCA were found in 8% of patients with benign diseases, 4% of NED patients, 22% of Mo patients, and in 76% of MT cases. In primary breast cancer MCA values were related to tumor size and nodal involvement. A trend toward a lower DFI in patients with elevated presurgical MCA levels was observed but was of no statistical significance. These differences became statistically significant when patients were subdivided according to nodal status, with shorter DFI in those without nodal invasion (p < 0.05). In metastatic patients, changes in serum MCA were related to the tumor's response to treatment in 82% of cases. The highest MCA values were found in patients with liver or bone metastasis and the lowest values were found in those with locoregional recurrence. In conclusion, although MCA is not a specific tumor marker, it can be useful as a prognostic factor (tissue and serum) and in monitoring metastatic patients.

Erlangen tumor marker study on breast cancer

1993 ◽  
Vol 29 ◽  
pp. S84
Author(s):  
W Jäger ◽  
M Ostrowski ◽  
S Krämer ◽  
N Lang
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Marker Study

Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker

2002 ◽  
Vol 12 (1) ◽  
pp. 74-79
Author(s):  
C Dimas ◽  
M Frangos-Plemenos ◽  
E Kouskouni ◽  
A Kondis-Pafitis
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Primary Breast Cancer ◽  
Immunohistochemical Study ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Progesterone Receptors ◽  
Her2 Overexpression ◽  
Serum Tumor Marker ◽  
Degree Of Differentiation

Abstract.Dimas C, Frangos-Plemenos M, Kouskouni E, Kondis-Pafitis A. Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker.Human epidermal growth factor receptor 2 (p185 HER2) oncoprotein immunohistochemical expression and DF3 antigen distribution were evaluated in 129 patients with primary breast cancer. p185 HER2 overexpession was positively correlated with the degree of differentiation, metastatic disease, progesterone receptors, and cytoplasmic distribution of DF3 antigen. p185 HER2 overexpression had prognostic significance for the disease-free interval.

Sign in / Sign up

Export Citation Format

Share Document